Care of Ebola Survivors and Factors Associated With Clinical Sequelae—Monrovia, Liberia

A. de St. Maurice,1,2,* E. Ervin,1 R. Orone,3 M. Choi,1 E.K. Dokubo,4 P.E. Rollin,1 S.T. Nichol,1 D. Williams,4 J. Brown,3 R. Sacra,3 J. Fankhauser,3 and B. Knust1

1Viral Special Pathogens Branch, Centers for Disease Control and Prevention, Atlanta, Georgia; 2Division of Pediatric Infectious Diseases, University of California Los Angeles, Los Angeles, California; 3ELWA Hospital, Monrovia, Liberia; 4Centers for Disease Control and Prevention, Monrovia, Liberia

Background. The Eternal Love Winning Africa (ELWA) Clinic was the first clinic to provide free, comprehensive care to Ebola virus disease (EVD) survivors in Liberia. The objectives of this analysis were to describe the demographics and symptoms of EVD survivors at ELWA from January 2015 through March 2017 and to identify risk factors for development of sequelae.

Methods. Patients’ demographic and clinical information was collected by chart review in June 2016 and March 2017. Associations with clinical sequelae were analyzed using the chi-square test, t test, and multivariate logistic regression.

Results. From January 2015 to March 2017, 329 EVD survivors were evaluated at ELWA. Most survivors experienced myalgia/arthralgia (73%; n = 239) and headache (53%; n = 173). The length of time from Ebola Treatment Unit (ETU) discharge to first clinic visit ranged from 0 to 30 months. Many visits (30%) occurred 24 or more months after ETU discharge. The proportion of visits for headache, weight loss, joint pain, visual problems, insomnia, fatigue, memory loss, decreased libido, depression, and uveitis decreased over time. More men than women had visits for depression; however, these differences were not significant. Symptom prevalence differed in adults and children; significantly more adults experienced myalgia/arthralgia (77% vs 44%), visual problems (41% vs 12%), post-EVD-related musculoskeletal pain (42% vs 15%), and insomnia (17% vs 2%).

Conclusions. EVD survivors frequented ELWA for EVD-related symptoms many months after ETU discharge, indicating a long-term need for care. Reported symptoms changed over time, which may reflect eventual resolution of some sequelae.

Keywords. Ebola; ELWA hospital; Liberia; Monrovia; survivors.

The 2014–2016 Ebola virus disease (EVD) epidemic resulted in >28 000 EVD cases and 11 000 deaths in West Africa [1]. There are an estimated 17 000 EVD survivors in West Africa, including an estimated 5000 survivors in Liberia. The Liberia Ministry of Health (MOH) maintains a registry of EVD survivors—persons who were admitted to an Ebola Treatment Unit (ETU) and tested positive for Ebola virus, and who subsequently tested negative for the virus on discharge from the ETU. However, only 1500 EVD survivors are registered in the Liberian MOH database [1].

Limited data exist regarding long-term consequences of EVD and optimal strategies for survivor care [2]. Studies of previous, smaller outbreaks noted that survivors suffered from arthralgias, fatigue, abdominal pain, ocular symptoms, hearing loss, and psychological symptoms [3–5]. Cross-sectional studies reported similar findings following the recent West Africa epidemic [2, 6–9]. Sequelae can have pronounced effects on survivor health and productivity [10]. Decreased visual acuity in particular may lead to difficulties with employment and daily activities. Timing of sequelae onset and duration among survivors is poorly understood. In some instances, Ebola survivors can develop severe ocular and neurologic conditions, including uveitis and meningitis, late after recovery; in 2 well-documented cases, virus was detected in ocular and cerebrospinal fluid months after clearance of viremia [11, 12]. Follow-up from a 2007 outbreak in Uganda demonstrated that survivors experienced symptoms more than 2 years after ETU discharge [3].

The World Health Organization developed guidance regarding care of common EVD sequelae and highlighted the need for comprehensive support of the medical and psychosocial challenges experienced by survivors [13]. However, it may be challenging for survivors to access health care services. Survivors may face stigma within their community and in certain instances have lost their jobs and become isolated from the community [14].

The Eternal Love Winning Africa (ELWA) hospital is a privately funded health care facility in Monrovia, Liberia. The first confirmed EVD case in Liberia occurred in March 2014, and the peak number of confirmed EVD cases occurred from August to September 2014 [15]. In March 2014, ELWA opened the first ETU in Monrovia, and it later expanded to become the largest ETU in Liberia. As the number of EVD survivors increased and more EVD complications were identified, ELWA worked with Liberia’s MOH-led Survivor Clinical Working Group to develop clinical guidelines to assess and treat survivors. In January 2015,
ELWA established an EVD Survivor Clinic, which is open 5 days a week and has provided care to >300 patients.

We reviewed clinical data from EVD survivors at the ELWA Clinic to assess symptoms and diagnoses following resolution of EVD infection and to identify risk factors for development of sequelae. We hypothesized that symptoms may differ by gender and age group and that patients who reported depression may be more likely to experience additional symptoms compared with patients without depression, as symptoms may have a significant impact on mental health through negative effects on quality of life and earning potential.

METHODS

Study Setting
The ELWA hospital, located in Paynesville City, Monrovia, was founded by the international mission organization Serving in Mission (SIM) in 1965. The hospital provides low-cost comprehensive care to the community, including obstetrics, surgical care, primary care, dental care, pediatrics, and HIV care. In the aftermath of the 2014–2016 Ebola outbreak, EVD survivors with either an ETU discharge certificate or reported history of EVD illness were provided a medical care card that allowed them to receive care at the ELWA hospital for no cost. Diagnostic tests regularly available in the clinic included complete blood count, Widal test, C-reactive protein, erythrocyte sedimentation rate, malaria smear, HIV testing, urine pregnancy test, urinalysis, chest x-ray, and basic metabolic profile. Slit lamp ocular examination was dependent on the availability of trained clinicians.

Data Collection and Analysis
In June 2016 and March 2017, we conducted a review of EVD Survivor Clinic outpatient medical charts dated January 1, 2015, through March 17, 2017. These dates were chosen to allow time between chart reviews and investigator availability. Patients were included in the analysis if they had a recorded ETU discharge date in their medical chart. The EVD Survivor Clinic used a standard form for each clinical visit, which collected historical information about dates of ETU admission and discharge, preexisting chronic conditions, and medical problems experienced while hospitalized with EVD. The form included a closed-ended list of medical problems experienced by patients since ETU discharge, and questions about self-reported depression and experiencing stigma. Physical exam findings, diagnoses, and medications prescribed were also recorded. Pediatric patients had a separate form with a similar structure.

Data were extracted from the above form using a data collection tool and entered into an electronic database. Demographic data, dates of ETU discharge and clinic visit, symptoms, and diagnoses at each visit were coded. Symptoms and diagnoses were coded by theme (e.g. gastrointestinal and musculoskeletal) and keywords. The symptoms selected for analysis were based on being most frequently reported: headache, abdominal pain, weight loss/decreased appetite, myalgia/arthralgia, visual problems, weakness, insomnia, fatigue, poor memory, pain/numbness in extremity, post-EVD musculoskeletal syndrome, malaria, urinary tract infection (UTI), respiratory tract infection, pelvic inflammatory disease (PID), dyspepsia/reflux, hypertension, typhoid, palpitations, stigma experience, anxiety, diarrhea, erectile dysfunction, irregular menses, hearing loss, decreased libido, depression, and uveitis. Post-EVD musculoskeletal syndrome is a term used by ELWA clinicians to define musculoskeletal pain following EVD recovery not attributable to another cause. Criteria for other diagnoses and symptoms are listed in Supplementary Table 1.

Statistical analysis was conducted using Stata 13 (StataCorp, College Station, TX). Time from ETU discharge was calculated by number of months from the recorded ETU discharge date to the date of clinic visit. Univariate analysis was performed using a chi-square test for categorical variables and t test for continuous variables. Multivariate logistic regression was used to determine the association between symptom prevalence and months from ETU discharge, adjusting for gender and age. Logistic regression analysis was also conducted to determine whether patients with depression were at greater odds of having a particular symptom or diagnosis, after adjusting for time from ETU discharge. The false discovery rate technique was used to adjust both the univariate and multivariate analyses with an overall alpha of .05 for multiple comparisons [16].

Ethics Statement
The project was reviewed and determined not to be human subjects research by the US Centers for Disease Control and Prevention and Liberia National Research Ethics Board.

RESULTS

Implementation and Chronology of the ELWA Survivor Clinic
In January 2015, ELWA opened the EVD survivor clinic in Monrovia and had a rapid increase in the caseload, with a monthly maximum of 152 recorded visits during April 2015 (Figure 1). Visits began to decline by September 2015, with fewer but consistent visits (20–40 per month) midway through 2016, and fewer than 10 visits per month at the time of data capture in 2017.

Medical records were available from 384 patients seen at the clinic from January 1, 2015, through March 17, 2017. Of these, 329 had a documented ETU discharge date. These 329 individuals contributed to 947 patient visits. The mean number of visits per patient (range, median) was 2.9 (1–33, 2). The mean age at first visit (range) was 33 (0.9–75) years (Table 1). Most patients were age (interquartile range) 18–49 (24–41) years, and 58% (95% confidence interval [CI], 53%–64%) of patients were female. The mean number of days since ETU discharge to first visit was 288 days. Most (60%; 95% CI, 57%–63%) patient visits
occurred 6–18 months after ETU discharge, although 11% (95% CI, 9%–13%) of visits occurred 24–30 months after discharge (Figure 2).

Symptoms and Diagnoses Observed
The most common symptoms experienced (Table 2) included myalgia/arthralgia (73%; 239/329), headache (53%; 173/329), abdominal pain (45%; 148/329), weight/appetite loss (41%; 135/329), vision problems (38%; 125/329), and fatigue (28%; 93/329). The most common diagnoses were post-EVD musculoskeletal syndrome (38%; 125/329), malaria (32%; 106/329), UTI (19%; 62/329), respiratory tract infection (11%; 36/329), PID (11%; 20/189), typhoid (9%; 30/329), and uveitis (5%; 16/329).

The symptoms and diagnoses of patients varied as the number of months from ETU discharge increased. There was a significant monthly decrease in the proportion of visits for headache, weight loss, experiencing stigma, extremity numbness or pain, joint pain, visual problems, insomnia, fatigue, poor memory, post-EVD musculoskeletal syndrome, hearing loss, decreased libido, depression, and uveitis ($P < .05$) (Table 3, Figure 3A and B). In contrast, there was a significant monthly increase in the proportion of visits for weakness, malaria, UTI, respiratory tract infection, and hypertension ($P < .05$) (Table 3, Figure 3C). When the analysis was limited to patients with only 3 or more visits, the results were similar (Supplementary Table 2).

Treatment Provided
Patients were treated with antidepressants and anxiolytics (eg, amitryptilline, diazepam), acid-suppressing medications (eg, lansoprazole), cholesterol-lowering medications (eg, statins), anti-inflammatory medications (eg, oral or topical ophthalmologic steroids, nonsteroidal anti-inflammatory drugs), antihypertensive medications (eg, furosemide, nifedipine, beta-blockers, angiotensin–converting enzyme inhibitors), vitamins and iron supplements, antimalarials, antihelminthic medications, antibiotics (eg, amoxicillin, ciprofloxacin, ceftriaxone), and oral contraceptives. Referrals to group therapy, surgery, dentistry, and ophthalmology were made as needed. Counseling and education were provided on diet, exercise, and other healthy lifestyle modifications.

Comparison of Symptoms and Diagnoses by Gender and Age Group
The prevalence of symptoms was stratified by gender (Table 2); however, these findings were no longer significant after adjusting for multiple comparisons.

Children <18 years of age comprised 13% of patients evaluated at ELWA (Table 1). Children had significantly more visits

---

**Table 1. Demographic Characteristics of Ebola Survivors at the ELWA Clinic**

| Characteristic | Values |
|---------------|--------|
| Sex, male/female, No. (%) | 135 (42)/189 (58) |
| Mean age at first visit, y | 33 (0.9–75) |
| Age group, No. (%) | |
| <5 y | 9 (3) |
| 5–17 y | 32 (10) |
| 18–49 y | 230 (70) |
| 50–64 y | 26 (8) |
| >65 y | 32 (9) |
| Mean time since ETU discharge to first visit, d | 288 (4–909) |

Abbreviations: ELWA, Eternal Love Winning Africa Clinic; ETU, Ebola Treatment Unit.
Table 2. Prevalence of Symptoms and Diagnoses Recorded at Clinic Visits

| Symptom                         | Total\( ^a \) (n = 329), No. (%) | Males (n = 139), No. (%) | Females (n = 189), No. (%) | \( P \) Value\( ^b \) | Children (n = 41), No. (%) | Adults (n = 288), No. (%) | \( P \) Value\( ^b \) |
|---------------------------------|-----------------------------------|--------------------------|----------------------------|----------------------|---------------------------|---------------------------|----------------------|
| **Myalgia/arthralgia**          | 239 (73)                          | 96 (71)                  | 143 (75)                   | .48                  | 18 (44)                   | 201 (77)                  | <.001\( ^c \)         |
| **Headache**                    | 173 (53)                          | 63 (47)                  | 107 (58)                   | .05                  | 16 (37)                   | 141 (54)                  | .038                 |
| **Abdominal pain**              | 148 (45)                          | 52 (39)                  | 95 (50)                    | .036                 | 13 (32)                   | 119 (45)                  | .62                  |
| **Weight loss/appetite loss**   | 135 (41)                          | 51 (38)                  | 84 (44)                    | .23                  | 12 (29)                   | 112 (43)                  | .10                  |
| **Vision problem**              | 125 (38)                          | 55 (41)                  | 69 (37)                    | .44                  | 5 (12)                    | 108 (41)                  | <.001\( ^c \)         |
| **Fatigue**                     | 93 (28)                           | 36 (27)                  | 57 (30)                    | .49                  | 5 (12)                    | 77 (30)                   | .021                 |
| **Pain/humbness in extremity**  | 60 (18)                           | 30 (22)                  | 30 (16)                    | .15                  | 3 (7)                     | 53 (20)                   | .047                 |
| **Gastritis**                   | 54 (16)                           | 24 (18)                  | 29 (15)                    | .56                  | 5 (12)                    | 46 (16)                   | .39                  |
| **Insomnia**                    | 50 (15)                           | 20 (15)                  | 30 (16)                    | .79                  | 2 (5)                     | 44 (17)                   | .016\( ^c \)          |
| **Weakness**                    | 46 (14)                           | 16 (120)                 | 28 (15)                    | .44                  | 8 (20)                    | 38 (13)                   | .27                  |
| **Irregular menses**            | -                                 | -                        | 24 (13)                    | -                    | -                         | -                         | -                    |
| **Experiencing stigma**         | 10 (3)                            | 6 (4)                    | 4 (2)                      | .23                  | -                         | -                         | -                    |
| **Decreased libido**            | 33 (10)                           | 16 (12)                  | 17 (9)                     | .4                   | -                         | -                         | -                    |
| **Diagnosis**                   |                                   |                          |                            |                      |                           |                           |                      |
| **Post-EVD musculoskeletal disease** | 125 (38)                      | 48 (36)                  | 76 (40)                    | .39                  | 9 (22)                    | 106 (40)                  | 0.005\( ^c \)         |
| **Malaria**                     | 106 (32)                          | 18 (13)                  | 46 (24)                    | .02                  | 12 (29)                   | 46 (16)                   | .005\( ^c \)          |
| **Urinary tract infection**     | 62 (19)                           | 17 (13)                  | 45 (24)                    | .01                  | 2 (5)                     | 56 (21)                   | .012\( ^c \)          |
| **Respiratory tract infection** | 36 (11)                           | 17 (13)                  | 18 (10)                    | .38                  | 11 (27)                   | 24 (9)                    | <.001\( ^c \)         |
| **Pelvic inflammatory disease** | -                                 | -                        | 20 (11)                    | -                    | -                         | -                         | -                    |
| **Typhoid**                     | 30 (9)                            | 11 (8)                   | 19 (10)                    | .56                  | 4 (10)                    | 24 (9)                    | .91                  |
| **Uveitis**                     | 16 (5)                            | 6 (4)                    | 10 (5)                     | .73                  | -                         | 14 (5)                    | -                    |
| **Depression**                  | 42 (13)                           | 23 (17)                  | 18 (10)                    | .045                 | 2 (5)                     | 39 (15)                   | .089                 |
| **Anxiety/worried**            | 44 (13)                           | 18 (13)                  | 26 (14)                    | .91                  | 3 (7)                     | 37 (14)                   | .23                  |
| **Poor memory**                 | 41 (12)                           | 15 (11)                  | 26 (14)                    | .48                  | 2 (5)                     | 34 (13)                   | .13                  |
| **Palpitations**                | 40 (12)                           | 13 (10)                  | 27 (14)                    | .21                  | 1 (2)                     | 36 (14)                   | .039                 |
| **Erectile dysfunction**        | -                                 | -                        | -                          | -                    | -                         | -                         | -                    |
| **Hypertension**                | 22 (7)                            | 10 (7)                   | 12 (6)                     | .57                  | -                         | -                         | -                    |
| **Hearing loss**                | 19 (6)                            | 7 (5)                    | 11 (6)                     | .81                  | 2 (5)                     | 14 (5)                    | .897                 |
| **Diarrhea/gastroenteritis**    | 14 (4)                            | 5 (4)                    | 8 (4)                      | .81                  | 4 (10)                    | 9 (3)                     | .06                  |

Abbreviation: EVD, Ebola virus disease.
\(^a\)In some instances, total includes patients without a sex or age recorded.
\(^b\)\(P\) value is significant after adjusting for multiple comparisons.
\(^c\)Univariate analysis using \(X^2\), adjusting for multiple comparisons.
for malaria (P = .005) and respiratory tract infections (P < .001), whereas adults had significantly more visits for myalgia/arthralgia (P < .001), vision problems (P < .001), post-EVD musculoskeletal disease (P = .001), UTI (P = .012), and insomnia (P = .016) (Table 2).

Association of Experiencing Depression With Other Symptoms

The association between patients experiencing depression and other symptoms was assessed for visits during the first 12 months since ETU discharge as symptoms of depression were generally reported during this time frame. Patients experiencing depression (n = 42 patients contributing to 47 patient visits) were significantly more likely to experience stigma, fatigue, palpitations, weight loss, decreased libido, insomnia, pain/numbness, visual problems, anxiety, headache, hearing loss, or diarrhea than patients without depression (Table 4). The strongest association with symptoms of depression was seen in patients who experienced stigma (odds ratio, 26; 95% CI, 4.8–140; P = .0002).

DISCUSSION

This analysis sought to better understand the development of symptoms in EVD survivors in Liberia in order to optimize care. Using data collected from the medical records during a 2-year time frame, we were able to identify symptoms and diagnoses commonly experienced by EVD survivors. We found that survivors most commonly experienced myalgia/arthralgia, headache, abdominal pain, and visual problems. These data are similar to those reported in the long-term follow-up of EVD survivors 2 years post-EVD in Uganda, where the most common symptoms experienced by EVD survivors included difficulty sleeping, fatigue, blurred vision, headache, and joint pain [3].

Although numerous studies have characterized EVD sequelae, few have examined the variation of sequelae over time. EVD survivors reported different symptoms early after ETU discharge than they reported months after ETU discharge. A previous comparison of survivors in acute convalescence (0–90 days after ETU discharge) with those in subacute convalescence (91–210 days after ETU discharge) found that the severity of anorexia and arthralgia decreased over time from ETU discharge [6]. Our analysis revealed that the proportion of visits for symptoms associated with acute convalescence, such as weight loss, visual problems, depression, and joint pain, also significantly decreased over time, particularly 12 months after ETU discharge. This finding was significant even when the analysis was limited to patients who had 3 or more visits at ELWA, suggesting that these symptoms may gradually improve due to the natural history of the disease or due to treatment. Weakness increased significantly over time; the underlying mechanism and whether this symptom was related to EVD are unclear. The proportion of visits for non-EVD-related conditions (such as malaria) increased over time, suggesting that EVD survivors began to seek care for more acute illnesses as their chronic symptoms improved. One potential explanation could be that survivors began to see the clinic as a trusted and free source of care and began to seek more regular care at ELWA.

These results suggest that musculoskeletal, visual, psychological, and gastrointestinal problems are most pronounced during the immediate recovery period. Although the exact mechanisms for these findings are not well understood, they may be mediated by immune system activation and viral persistence. EVD triggers a robust immune response and a “cytokine storm” by nonspecifically activating T cells and leading to cytokine production, particularly IL-4 and IFN-gamma [17]. Viral antigen persistence may also trigger persistent immune response and may contribute to persistence of symptoms. In patients with Ebola treated in the United States, abnormalities in cellular immunity were noted for longer than 1 month after recovery from EVD [18]. For example, fractalkine (a marker of T-cell activity that has also been associated with chronic inflammatory diseases including rheumatoid arthritis [19, 20]), remained elevated up to 15 months after recovery from EVD [18]. Further research is needed to better understand the disease process and recovery.

This analysis also revealed an association between age and symptom prevalence. Children accounted for >18% of confirmed Ebola cases in Liberia [15] and for 13% of patients included in this analysis. Children <5 years of age have higher

---

### Table 3. Association of Symptoms/Diagnoses With Increasing Months From ETU Discharge

| Symptom, Complaint, or Diagnosis | Odds Ratio | 95% Confidence Interval | P Value |
|---------------------------------|-----------|------------------------|---------|
| Visual problem                  | 0.9       | 0.87–0.92              | <.001   |
| Fatigue                         | 0.92      | 0.88–0.95              | <.001   |
| Depression                      | 0.87      | 0.82–0.93              | <.001   |
| Uveitis                         | 0.79      | 0.73–0.86              | <.001   |
| URTI                            | 1.1       | 1.04–1.11              | .001    |
| Headache                        | 0.96      | 0.94–0.98              | .0004   |
| URTR/LRTI                       | 1.1       | 1.03–1.12              | .0005   |
| Post-EVD musculoskeletal syndrome | 0.96    | 0.93–0.98              | .0008   |
| Decreased libido                | 0.90      | 0.85–0.96              | .001    |
| Malaria                         | 1.04      | 1.02–1.11              | .001    |
| Poor memory                     | 0.9       | 0.86–0.96              | .0012   |
| Weakness                        | 1.1       | 1.02–1.11              | .0015   |
| Joint pain                      | 0.97      | 0.95–0.99              | .0018   |
| Hypertension                    | 1.06      | 1.02–1.11              | .0028   |
| Insomnia                        | 0.94      | 0.91–0.98              | .0048   |
| Hearing loss                    | 0.87      | 0.78–0.96              | .007    |
| Weight loss                     | 0.97      | 0.95–0.99              | .0189   |
| Experiencing stigma             | 0.84      | 0.73–0.97              | .019    |

Abbreviations: ETU, Ebola Treatment Unit; EVD, Ebola virus disease; URTR/LRTI, upper respiratory tract infection/lower respiratory tract infection; UTI, urinary tract infection.

*Using multivariate logistic regression, adjusting for sex and age and correcting for multiple comparisons.
Figure 3. Changes in the prevalence of symptoms per clinic visit since Ebola Treatment Unit (ETU) discharge. Only those that had a significant change in incidence over time are shown in these figures (P < .05). Data for those that were nonsignificant are in Supplementary Table 1. A, Proportion of visits for headache, weight loss, joint pain, visual problem, insomnia, and fatigue during each 6-month period from ETU discharge date. B, Proportion of visits for poor memory, post–Ebola virus disease musculoskeletal syndrome (post-EVD MSK syndrome), hearing loss, decreased libido, depression, and uveitis during each 6-month time period. C, Proportion of visits for weakness, malaria, urinary tract infection (UTI), respiratory tract infection (RTI), and hypertension during each 6-month period.
case fatality ratios than older children, which may result from a variety of factors, including nutritional status and immunologic response [21]. In this study, children and adults experienced different symptoms, with more adults reporting headache, post-EVD musculoskeletal syndrome, fatigue, insomnia, palpitations, visual problems, and joint problems. This may be due to difficulties in diagnosing some of these symptoms in children as they may be unable to articulate symptoms and physical examination may be more challenging. Differences in age-associated comorbidities may also play a role; in our study, children were noted to have more malaria, which may affect the immune response to other infections such as Ebola. Immune response in pediatric EVD patients has been demonstrated to differ from adults regardless of comorbidities, with children noted to have higher levels of markers of cellular adhesion molecules, cytokines (including RANTES), and macrophage colony-stimulating factor compared with adults [22]. These differences in immune response may also manifest in terms of post-EVD sequelae. Physicians caring for EVD survivors should be sure to examine all children thoroughly and discuss potential for symptom development with their caregivers.

Depression at ELWA was diagnosed by patient report of feeling sad, overwhelmed, or “blue.” Our study found that depression was associated with additional symptoms experienced by EVD survivors. Our findings are similar to those of a study of survivors in Guinea where patients with myalgia/arthralgia were found to have higher rates of depression [23]. Some patients may experience physical complaints as a result of depression or post-traumatic stress disorder [24]. On the other hand, patients with multiple physical complaints may also experience depression as a result of having more symptoms and interference with activities of daily living. Both physical complaints and depression may improve with a combination of medications, physical therapy, and mental health treatment. Liberia has limited mental health care facilities [25], and there are no validated screening tools for depression in this population. Given our findings, mental health care should be strengthened so that depression in EVD survivors can be diagnosed and treated systematically.

ELWA provided a range of treatments for survivors to treat illnesses such as hypertension, depression, or joint pain. In some instances, as the etiology of symptoms was unclear, treatment was focused on symptomatic relief. Patients with musculoskeletal pain anecdotally reported improvement with medications such as anti-inflammatory medications and steroids. Similarly, EVD survivors have reported gastritis symptoms, which have anecdotally responded to treatment with acid suppression therapy (eg, proton pump inhibitors). As our study was retrospective and patients had irregular follow-up intervals, we were unable to quantify whether these treatments were efficacious. However, when we limited our analysis to patients who returned for 3 or more visits, we found that many EVD-related symptoms appeared to decrease over time, including visual problems and post-EVD musculoskeletal pain. Responders planning for further EVD survivor care should consider providing medications for symptomatic relief of survivors and should prospectively collect data on the outcomes of various treatment regimes.

This study is subject to several limitations. Some information in the charts was missing or illegible. We only reviewed outpatient records and did not review hospital admissions. All data were collected retrospectively as part of clinical care, and our study lacked a control group. As a result, we were only able to determine symptoms of patients who sought care in the facility, and it was difficult to distinguish if the clinical experience observed in EVD survivors was unique to their EVD sequelae and distinct from the general population. As we only captured information about patients who sought care at ELWA, we did not have information about EVD survivors who may not seek care because they are asymptomatic. This may explain why a greater proportion of EVD survivors seen at ELWA experienced symptoms than the proportion reported in the Uganda study [3]. Other studies conducted during the 2014–2016 outbreak have similarly described high rates of musculoskeletal pain and headache [6–8, 26], suggesting that selection bias alone may not explain the high rates in our study.

In conclusion, we found that EVD survivors continued to seek care at ELWA for more than 2 years after ETU discharge. As such, physicians should expect to treat sequelae in EVD survivors long after discharge. Symptoms reported differ by patient age and time since ETU discharge. At ELWA, effective survivor care was provided within the existing structure of the hospital, was set up quickly (within months), and continued for more than 2 years without interruptions. Support for EVD survivor services in West Africa should be continued, and funding for support of survivors should be included in planning for future EVD outbreak responses in order to ensure provision of

| Symptom/Diagnosis          | Adjusted Odds Ratio | 95% Confidence Interval | P Value |
|----------------------------|---------------------|-------------------------|---------|
| Experiencing stigma         | 26                  | 4.8–140                 | .0002   |
| Fatigue                    | 5.2                 | 2.5–10                  | <.0001  |
| Palpitations               | 6.7                 | 2.6–17                  | .0001   |
| Weight loss                | 3.7                 | 1.9–73                  | .0002   |
| Decreased libido           | 5.9                 | 2.3–15                  | .0002   |
| Insomnia                   | 4.4                 | 1.9–10                  | .0005   |
| Pain numbness in feet      | 3.9                 | 1.7–8.8                 | .0011   |
| Visual problem             | 2.9                 | 1.5–5.7                 | .0021   |
| Anxiety                    | 4.1                 | 1.5–11                  | .0068   |
| Headache                   | 2.6                 | 1.3–5.0                 | .0078   |
| Hearing loss               | 4.7                 | 1.3–16                  | .0155   |
| Diarrhea                   | 5.6                 | 1.3–24                  | .0204   |

Abbreviations: ETU, Ebola Treatment Unit; EVD, Ebola virus disease.
*AAdjusting for multiple comparisons and time from ETU discharge.*
adequate care both during acute infection and in the postrecovery period. Given the chronicity of EVD-related sequelae, consideration should be given to funding and strengthening existing medical infrastructure in-country to ensure long-term follow-up and care.

**Supplementary Data**

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

**Acknowledgments**

We would like to acknowledge the Liberia Centers for Disease Control and Prevention (CDC) country office and the Eternal Love Winning Africa clinic staff, including Nancy Writebol, for their support for this project.

**Disclaimer.** The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the CDC.

**Financial support.** This work was supported by CDC Ebola outbreak response funds.

**Potential conflicts of interest.** All authors: no reported conflicts of interest or funding sources. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. WHO. Ebola situation report-30 March 2016. http://apps.who.int/ebola/current-situation/ebola-situation-report-30-march-2016. Accessed May 19, 2017.

2. Vetter P, Kaiser L, Schibler M, et al. Sequelae of Ebola virus disease: the emergency within the emergency. Lancet Infect Dis 2016; 16:e82–91.

3. Clark DV, Kibuuka H, Millard M, et al. Long-term sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. Lancet Infect Dis 2015; 15:905–12.

4. Rowe AK, Bertolli J, Khan AS, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. Commission de Lutte contre les Épidémies à Kikwit. J Infect Dis 1999; 179(Suppl 1):S28–35.

5. Kibadi K, Mupapa K, Kuvula K, et al. Late ophthalmologic manifestations in survivors of the 1995 Ebola virus epidemic in Kikwit, Democratic Republic of the Congo. J Infect Dis 1999; 179(Suppl 1):S13–4.

6. Qureshi AI, Chughtai M, Loza TO, et al. Study of Ebola virus disease survivors in Guinea. Clin Infect Dis 2015; 61:1035–42.